CORO2A

Across TCGA pan-cancer cohorts, CORO2A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CORO2A data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CORO2A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CORO2A expression acts as an unfavorable survival marker.

HNSC, PRAD, and LUSC are the cancer types where CORO2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.192	0.628	.013	21	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CORO2A–HNSC (DFS)

Open the HNSC breakdown →